Minocycline compounds for biodefense

Inventors

DRAPER, MICHAEL P. • Tanaka, S. Ken

Assignees

Paratek Pharmaceuticals Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-11129839-B2

Patent

Publication Date

2021-09-28

Expiration Date


Abstract

Methods of treating or preventing a bacterial infection in a subject are disclosed herein, wherein the bacterial infection is caused by a bacterium which can be used as a biological weapon. Also disclosed is a pharmaceutical composition comprising the compound of the present invention for treating or preventing a bacterial infection in a subject, wherein the bacterial infection is caused by a bacterium which can be used as a biological weapon.

Core Innovation

The patent describes administering an effective amount of Compound A′, identified as omadacycline, to treat or prevent bacterial infection in a subject in need thereof. The independent claim addresses infection caused by Bacillus anthracis, identified as a bacterium that can be used as a biological weapon, in powder or aerosol form.

The description reports in vitro antibacterial activity against target pathogens, including tetracycline-resistant isolates, and in vivo efficacy for Compound A. It reports survival benefits and efficacy in post-exposure aerosol challenge models involving Bacillus anthracis, Yersinia pestis, and Burkholderia mallei comparable to doxycycline and ciprofloxacin.

Claims Coverage

The provided claims identify one independent claim with two inventive features covering the treatment or prevention of infection caused by weapon-usable bacteria.

Treatment or prevention of bacterial infection

The claim covers treating or preventing a bacterial infection in a subject in need thereof by administering an effective amount of Compound A′.

Infection caused by powder or aerosol Bacillus anthracis

The claimed infection is caused by Bacillus anthracis in powder or aerosol form, identified as a bacterium usable as a biological weapon.

The independent claim combines administration of an effective amount of Compound A′ with a limitation to treating or preventing infection caused by Bacillus anthracis in powder or aerosol form.

Stated Advantages

Compound A demonstrates in vitro antibacterial activity against target pathogens, including Bacillus anthracis and tetracycline-resistant isolates.

Post-exposure studies report survival benefits against Yersinia pestis, Bacillus anthracis, and Burkholderia mallei, demonstrating efficacy in an aerosol Bacillus anthracis mouse model comparable to doxycycline and ciprofloxacin.

Documented Applications

Treating or preventing bacterial infection caused by Bacillus anthracis in powder or aerosol form.

Post-exposure treatment or prevention of infections in aerosol challenge models involving Yersinia pestis, Bacillus anthracis, and Burkholderia mallei.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.